CA
NZ
UK
AU
IND
US
…
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -55.65M | -38.24M | -47.85M | -34.57M | -30.29M |
| Net income | -53.94M | -38.34M | -47.95M | -34.61M | -30.34M |
| Selling general administrative | - | 16.53M | 15.22M | 13.02M | 10.85M |
| Gross profit | -2.10M | 0.04M | 0.30M | 0.29M | 0.01M |
| Reconciled depreciation | - | 0.01M | 3.13M | 3.30M | 2.98M |
| Ebit | - | -38.17M | -47.21M | -34.49M | -20.94M |
| Ebitda | -66.84M | -38.17M | -44.08M | -31.19M | -17.96M |
| Depreciation and amortization | - | 0.01M | 3.13M | 3.30M | 2.98M |
| Operating income | -66.84M | -38.17M | -36.62M | -34.51M | -19.92M |
| Other operating expenses | 69.54M | 41.81M | 36.92M | 34.80M | 19.93M |
| Interest expense | 0.11M | 0.07M | 0.64M | 0.09M | 9.35M |
| Tax provision | - | 0.10M | 0.10M | 0.04M | 0.04M |
| Interest income | - | 0.89M | 0.05M | 0.15M | - |
| Net interest income | - | 0.33M | -0.59M | 0.06M | -9.35M |
| Income tax expense | -0.05M | 0.10M | 0.10M | 0.04M | 0.04M |
| Total revenue | 2.71M | 3.63M | 0.30M | 0.29M | 0.01M |
| Total operating expenses | 64.73M | 38.21M | 36.92M | 34.80M | 19.93M |
| Cost of revenue | 4.81M | 3.59M | 0.00M | 0.00M | - |
| Total other income expense net | 11.18M | -0.07M | -11.23M | -0.07M | -10.38M |
| Net income from continuing ops | - | -38.34M | -47.95M | -34.61M | -30.34M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 60.14M | 86.48M | 72.04M | 74.95M | 83.38M |
| Intangible assets | - | 46.57M | 49.09M | 58.54M | 56.08M |
| Other current assets | 0.34M | 0.34M | 3.29M | 0.13M | 0.23M |
| Total liab | 37.81M | 43.61M | 44.68M | 29.37M | 20.42M |
| Total stockholder equity | 24.69M | 44.79M | 28.12M | 44.38M | 62.96M |
| Other current liab | 13.43M | 6.87M | 11.14M | 10.27M | 6.69M |
| Common stock | 209.95M | 176.56M | 100.68M | 97.23M | 86.76M |
| Capital stock | - | 176.56M | 100.68M | 97.23M | 86.76M |
| Retained earnings | -199.67M | -145.73M | -111.34M | -65.35M | -30.82M |
| Cash | 4.14M | 29.12M | 18.58M | 11.70M | 26.98M |
| Total current liabilities | 18.90M | 14.93M | 17.58M | 13.23M | 7.88M |
| Current deferred revenue | - | 1.72M | - | - | - |
| Net debt | -4.14M | -29.12M | -18.58M | -11.70M | -26.98M |
| Other stockholder equity | 14.41M | 0.85M | 0.85M | 2.15M | - |
| Total current assets | 21.93M | 39.85M | 22.85M | 16.30M | 27.26M |
| Long term investments | - | 0.00M | 0.04M | - | - |
| Net receivables | 17.45M | 10.40M | 0.99M | 4.47M | 0.06M |
| Accounts payable | 5.47M | 6.35M | 6.43M | 2.96M | 1.19M |
| Accumulated other comprehensive income | - | 13.12M | 37.93M | 10.36M | 7.03M |
| Non currrent assets other | - | - | 0.04M | 0.04M | 0.04M |
| Non current assets total | 38.21M | 46.63M | 49.19M | 58.65M | 56.12M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | 1.77M | -0.32M | -1.53M | -28.37M |
| Total cashflows from investing activities | -5.30M | 1.77M | -0.32M | -1.53M | -28.37M |
| Net borrowings | - | -1.90M | 2.20M | 0.00M | -0.06M |
| Total cash from financing activities | 32.65M | 45.43M | 30.20M | 9.22M | 65.11M |
| Net income | -53.94M | -38.34M | -47.95M | -34.61M | -30.34M |
| Change in cash | -23.41M | 10.54M | 6.88M | -15.28M | 26.95M |
| Begin period cash flow | 27.54M | 18.58M | 11.70M | 26.98M | 0.03M |
| End period cash flow | 4.14M | 29.12M | 18.58M | 11.70M | 26.98M |
| Total cash from operating activities | -51.63M | -36.65M | -22.98M | -23.20M | -9.92M |
| Issuance of capital stock | - | 53.98M | 29.65M | 10.07M | 70.00M |
| Depreciation | 0.01M | - | - | - | - |
| Other cashflows from investing activities | - | 1.77M | -0.32M | -1.49M | -28.37M |
| Sale purchase of stock | - | - | -1.53M | -0.85M | -4.83M |
| Other cashflows from financing activities | - | -6.65M | -0.12M | - | - |
| Capital expenditures | 51.63M | 0.00M | 0.00M | 1.53M | 28.34M |
| Other non cash items | 2.31M | -36.65M | 24.97M | 11.41M | 20.42M |
| Free cash flow | - | -36.65M | -22.98M | -24.73M | -38.25M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| RADX Radiopharm Theranostics Limited American Depositary Shares |
-0.04 3.26% |
1.08 | - | - | 1.63 | 1.66 | 12.61 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 |
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
62 Lygon Street, Carlton, VIC, Australia, 3053
61 3 9824 5254
14
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Founder & Executive Chairman | 1956 |
| Mr. Riccardo Canevari | MD, CEO & Director | NA |
| Dr. Dimitris Voliotis M.D. | Chief Medical Officer | 1964 |
| Mr. Aaron Laurita | Chief Financial Officer | NA |
| Mr. Hitesh Goel | Head of Project Management | NA |
| Mr. Nathan Jong C.A. | Joint Company Secretary | NA |
| Ms. Amritha Sushil | Joint Company Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...